Wolfe Research Initiates Coverage on Krystal Biotech

Analysts issue 'peer perform' rating on NASDAQ:KRYS stock

Mar. 27, 2026 at 12:06pm

Got story updates? Submit your updates here. ›

Equities researchers at Wolfe Research have initiated coverage on shares of Krystal Biotech (NASDAQ:KRYS), issuing a 'peer perform' rating on the stock. The biotechnology company is focused on developing gene therapies for rare dermatological diseases.

Why it matters

Krystal Biotech's lead product candidate, KB103, is designed to treat dystrophic epidermolysis bullosa (DEB), a severe and debilitating blistering condition. Wolfe Research's coverage initiation and 'peer perform' rating provide an important third-party assessment of the company's prospects as it advances its pipeline.

The details

In addition to Wolfe Research's coverage initiation, several other equity research analysts have also weighed in on Krystal Biotech recently. Weiss Ratings lowered the company's rating from 'buy (b-)' to 'hold (c+)', while Zacks Research downgraded it from 'strong-buy' to 'hold'. However, TD Cowen and Chardan Capital maintained 'buy' ratings, with Charcard lifting its price target from $220 to $323.

  • Wolfe Research initiated coverage on Krystal Biotech on Friday, March 27, 2026.

The players

Krystal Biotech

A clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. The company's lead product candidate, KB103, is designed to treat dystrophic epidermolysis bullosa (DEB).

Wolfe Research

An equity research firm that has initiated coverage on Krystal Biotech, issuing a 'peer perform' rating on the stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

Krystal Biotech's gene therapy pipeline, particularly its lead candidate KB103 for treating DEB, continues to draw interest and mixed assessments from Wall Street analysts. The company's ability to advance its therapies through clinical development and regulatory approval will be key to unlocking value for investors.